Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Acute Ischemic Stroke Overview | 9 | 1 |
| Therapeutics Development | 10 | 1 |
| Pipeline Products for Acute Ischemic Stroke Overview | 10 | 1 |
| Acute Ischemic Stroke Therapeutics under Development by Companies | 11 | 2 |
| Acute Ischemic Stroke Pipeline Products Glance | 13 | 3 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Acute Ischemic Stroke Products under Development by Companies | 16 | 2 |
| Acute Ischemic Stroke Companies Involved in Therapeutics Development | 18 | 17 |
| AB Science SA | 18 | 1 |
| AstraZeneca Plc | 19 | 1 |
| Biogen Inc | 20 | 1 |
| D-Pharm Ltd. | 21 | 1 |
| Daiichi Sankyo Company, Limited | 22 | 1 |
| DiaMedica Inc. | 23 | 1 |
| Digna Biotech, S.L. | 24 | 1 |
| Glucox Biotech AB | 25 | 1 |
| Jeil Pharmaceutical Co., Ltd. | 26 | 1 |
| Lumosa Therapeutics Co., Ltd. | 27 | 1 |
| Mitsubishi Tanabe Pharma Corporation | 28 | 1 |
| Pharmicell Co., Ltd. | 29 | 1 |
| PhytoHealth Corporation | 30 | 1 |
| Remedy Pharmaceuticals, Inc. | 31 | 1 |
| Saneron CCEL Therapeutics, Inc. | 32 | 1 |
| Simcere Pharmaceutical Group | 33 | 1 |
| Stemedica Cell Technologies, Inc. | 34 | 1 |
| Acute Ischemic Stroke Therapeutics Assessment | 35 | 11 |
| Assessment by Monotherapy Products | 35 | 1 |
| Assessment by Target | 36 | 3 |
| Assessment by Mechanism of Action | 39 | 3 |
| Assessment by Route of Administration | 42 | 2 |
| Assessment by Molecule Type | 44 | 2 |
| Drug Profiles | 46 | 66 |
| 3K3A-APC Drug Profile | 46 | 2 |
| AB-022 Drug Profile | 48 | 1 |
| ApTLR-4FT Drug Profile | 49 | 1 |
| Cellgram-IS Drug Profile | 50 | 1 |
| DB-017 Drug Profile | 51 | 1 |
| DM-199 Drug Profile | 52 | 4 |
| DS-1040 Drug Profile | 56 | 1 |
| glyburide Drug Profile | 57 | 4 |
| HBI-002 Drug Profile | 61 | 1 |
| HBN-1 Drug Profile | 62 | 1 |
| JPI-289 Drug Profile | 63 | 1 |
| LT-3001 Drug Profile | 64 | 1 |
| masitinib Drug Profile | 65 | 14 |
| MP-124 Drug Profile | 79 | 1 |
| natalizumab Drug Profile | 80 | 4 |
| Neu-2000 Drug Profile | 84 | 2 |
| Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis Drug Profile | 86 | 1 |
| PHN-014 Drug Profile | 87 | 1 |
| Rejuveinix Drug Profile | 88 | 1 |
| SIM-071201 Drug Profile | 89 | 1 |
| Small Molecule-1 to Inhibit NOX-4 for Acute Ischemic Stroke Drug Profile | 90 | 1 |
| Small Molecule-2 to Inhibit NOX-4 for Acute Ischemic Stroke Drug Profile | 91 | 1 |
| Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology Drug Profile | 92 | 6 |
| Stem Cell Therapy for Neurological and Cardiovascular Diseases Drug Profile | 98 | 2 |
| THR-18 Drug Profile | 100 | 3 |
| ticagrelor Drug Profile | 103 | 8 |
| TMS-007 Drug Profile | 111 | 1 |
| Acute Ischemic Stroke Dormant Projects | 112 | 3 |
| Acute Ischemic Stroke Discontinued Products | 115 | 2 |
| Acute Ischemic Stroke Product Development Milestones | 117 | 12 |
| Featured News &Press Releases | 117 | 1 |
| Sep 12, 2016: DiaMedica Announces Regulatory Clearance to Initiate Bridging Clinical Trial for DM199 | 117 | 1 |
| Jun 14, 2016: DiaMedica Announces U.S. Composition of Matter Patent for DM199 | 117 | 1 |
| Feb 02, 2016: DiaMedica Provides Update on DM199 Opportunity in South East Asia | 117 | 1 |
| Jan 05, 2016: CNS-Related Edema Company Remedy Pharmaceuticals Strengthens Leadership Team in Preparation for Phase 3 Trial | 118 | 1 |
| Nov 04, 2015: DiaMedica Provides Corporate Update | 118 | 2 |
| Oct 09, 2015: Remedy Pharmaceuticals Drug CIRARA Cut Death Rates from Severe Stroke by More Than Half | 120 | 3 |
| Sep 29, 2015: Remedy Pharmaceuticals Announces Phase 2 Severe Stroke Study Results to Be Presented at Neurocritical Care Annual Meeting | 123 | 1 |
| Mar 19, 2015: DiaMedica to Present at the 12th Annual BIO Asia International Conference | 123 | 1 |
| Dec 18, 2014: D-Pharm Achieves Primary End-point in Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated With tPA | 123 | 1 |
| Nov 04, 2014: D-Pharm Reports First Results From its Phase 2 Clinical Study of THR-18 In Acute Stroke Patients Treated with tPA | 124 | 1 |
| Aug 19, 2014: US Department of Justice Closes Investigation into PLATO Clinical Trial for BRILINTA | 125 | 1 |
| Jun 02, 2014: D-Pharm Reports Completion of the Second Dose Tier in its Phase 2 Clinical Study of THR-18 in Acute Stroke Patients Treated with the Thrombolytic Drug tPA | 125 | 1 |
| Apr 22, 2014: ZZ Biotech Announces Phase 2 Trial with 3K3A-APC in Stroke; Funds Will Be Provided by NIH and Broadview Ventures | 126 | 1 |
| Mar 04, 2014: D-Pharm reports the successful interim analysis of its Phase 2 clinical study of THR-18 in acute stroke patients | 127 | 1 |
| Jan 21, 2014: D-Pharm completes recruitment of patients into the first dosage tier of its Phase 2 study with THR-18 in acute stroke patients treated with tPA | 127 | 2 |
| Appendix | 129 | 2 |
| Methodology | 129 | 1 |
| Coverage | 129 | 1 |
| Secondary Research | 129 | 1 |
| Primary Research | 129 | 1 |
| Expert Panel Validation | 129 | 1 |
| Contact Us | 129 | 1 |
| Disclaimer | 130 | 1 |